USPTO 2015–2025 USPTO PatentsView US Corporation

EyePoint Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 21 granted patents across 8 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

RSS updates for this company

The verdict

According to USPTO PatentsView, Eyepoint ranks #13,984 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 8 technology areas.

#13,984
of 49,997 US assignees by volume
Top 13%
by Innovation Score (50.7/100)
18.9
avg claims per patent
+433%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13984 · US Corporation #13,984 · 21 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-SMALL 21 grants
  • MID-PACK #13,984/49,997
  • PHOTO-FINISH Evonik Oxeno & KG
  • CPC-NARROW A61K · 8 areas
  • INNOV-PAR 50.7/100
  • CLAIMS-RICH 18.9 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +433% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Evonik Oxeno GmbH & Co. KG (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Eyepoint’s 50.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Eyepoint

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Eyepoint's Innovation Score is 50.7/100 (top 13% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Eyepoint?

Each dot is one of Eyepoint’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Eyepoint’s own 18.9 claims/patent is ABOVE the 18.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Eyepoint vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 20.920.92121.1 1020304050 Granted patents (volume) Avg claims / patent Evonik Oxeno GmbH & Co. KG - 21, 16.29Evonik Oxeno & KGExabeam, Inc. - 21, 20ExabeamExcelitas Canada, Inc. - 21, 20.86Excelitas CanadaExegy Incorporated - 21, 40.48Exegy IncorporatedEyenovia, Inc. - 21, 20.24EyenoviaFlashsilicon Incorporation - 21, 16.81Flashsilicon Inco…Freevalve AB - 21, 17.62Freevalve ABFTI Consulting Technology LLC - 21, 18.48FTI Consulting Te…EyePoint Pharmaceuticals, Inc. - 21, 18.9Eyepoint Pharmace…
Eyepoint vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Eyepoint's grants concentrate

EyePoint Pharmaceuticals, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 71.4% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2024 (8 grants) versus a trough of 2 in 2021. By volume, Eyepoint sits between Evonik Oxeno GmbH & Co. KG and FTI Consulting Technology LLC.

Eyepoint's three-year grant acceleration

EyePoint Pharmaceuticals, Inc. shows 14 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at EyePoint's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows EyePoint holds 21 patents at rank #13,982, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near EyePoint

By rank, the assignees closest to #13,982 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in EyePoint's primary technology class.

Eyepoint's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

51 Top 13% higher than 87% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0246810 201920212022202320242025 2
USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table
EyePoint Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2019 3 14.3%
2021 2 9.5%
2022 3 14.3%
2023 3 14.3%
2024 8 38.1%
2025partial year 2 9.5%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

EyePoint Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

  • EyePoint Pharmaceuticals, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 71.4% of its portfolio - see every assignee active in that class. Explore A61K
  • Ranked #13,984 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare EyePoint Pharmaceuticals, Inc. against Evonik Oxeno GmbH & Co. KG, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 50.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.